OrbusNeich Honored with CAPITAL Outstanding Enterprise Award Recognized for Excellence in Medical Device Industry

(Hong Kong, April 28, 2026) – OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a multinational medical device company specializing in interventional solutions for percutaneous coronary intervention (“PCI”) and percutaneous transluminal angioplasty (“PTA”) procedures, was honored with the “Capital Outstanding Enterprise Award – Outstanding Medical Device Solution” in the Medical Equipment category at the 26th “Capital Outstanding Listed Company Awards & Capital Outstanding Enterprise Awards”.

This recognition highlights OrbusNeich’s contributions to the global medical device industry, showcasing the Group’s robust product portfolio, pioneering technology in interventional cardiology, and commitment to advancing patient-centered care through innovation.

Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeich, said, “At OrbusNeich, our mission is to improve patient outcomes through pioneer cardiovascular technologies. This award reflects the strength of our global platform and our commitment to delivering life-enhancing solutions to physicians and patients worldwide. We are honored that CAPITAL has recognized our ongoing efforts to lead through innovation and excellence.”

The CAPITAL Outstanding Enterprise Awards, organized by CAPITAL Magazine, honor organizations that have made remarkable contributions to Hong Kong’s economy and broader society. The awards are evaluated across three core pillars: corporate activity, governance, and social responsibility, thereby honoring companies that have demonstrated comprehensive excellence in business performance, innovation, and customer impact in 2025.

Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeich (left), receives the 26th Capital Outstanding Enterprise Awards on behalf of the Group.

－ End －

About OrbusNeich Medical Group Holdings Limited
OrbusNeich is a multinational medical device company specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, our Group sells its products in more than 70 countries and regions worldwide. It is also actively expanding into structural heart disease. With an in-house R&D team boasting over 20 years of product development expertise, our Group has developed world-leading proprietary technologies.

For more information, please visit the Group’s official website: https://orbusneich.com/.